A review of various antisense oligonucleotide therapeutic approaches for prostate cancer

Prostate Journal

Volumn 2, Issue 4, 2000, Pages 179-188

  Rubenstein, Marvin ^a   Guinan, Patrick ^a  

^a Hektoen Institute for Medical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN BINDING PROTEIN; ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; CALRETICULIN; CAVEOLIN; CGP 69846A; DNA DIRECTED DNA POLYMERASE ALPHA; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR; FORIVIRSEN; GENE EXPRESSION MODULATOR 231; GENE EXPRESSION MODULATOR 92; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; ISIS 13312; ISIS 3521; PROTEIN BCL 2; RAF PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL DESTRUCTION; DRUG EFFECT; DRUG EFFICACY; GENE EXPRESSION; GENE THERAPY; HOMEOBOX; HUMAN; MALE; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SHORT SURVEY;

EID: 0033634825     PISSN: 10955100     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1411.2000.24002.x     Document Type: Short Survey

References (30)

1. Cancer statistics, 2000
2. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
3. Mechanisms of action and clinical uses of estramustine
4. Role of Rnase H in hybrid-arrested translation by antisense oligonucleotides
5. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligonucleotide
6. Antisense oligonucleotide treatment of prostate cancer
7. Inoculation of prostatic tumors with antisense oligonucleotides against mRNA encoding growth factors and receptors
8. Antitumor activity of a c-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice
9. Abrogation of c-Raf expression induces apoptosis in tumor cells
10. Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: A novel therapy in prostate cancer
11. Antisense c-myc retroviral vector suppresses established human prostate cancer
12. Antisense inhibition of the PTI-1 oncogene reverses cancer phenotypes
13. Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides
14. Growth factor deprivation therapy utilizing antisense oligonucleotides
15. Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice
16. Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl) all-trans retinamide
17. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model
18. Progression to androgen indepenclence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model
19. Development of a hammerhead ribozyme against bcl-2: I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer
20. Development of a hammerhead ribozyme against Bcl-2: II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptosis
21. Prostate-specific antigen promoter driven gene therapy targeting DNA potymerase-alpha and topoisomerase II alpha in prostate cancer
22. Down-regulation of homeobox gene GBX2 expression inhibits human prostate cancer clonogenic ability and tumorgenicity
23. ETS2 function is required to maintain the transformed state of human prostate cancer cells
24. Calreticulin expression is associated with androgen regulation of the sensitivity to calcium ionophore-induced apoptosis in LNCaP prostate cancer cells
25. Suppression of caveolin expression induces androgen sensitivity in metastatic androgeninsensitive mouse prostate cancer cells
26. Suppression of prostate carcinoma cell invasion by expression of antisense L-plastin gene
27. Enhanced expression of bcl-2 following antisense oligonucleotide mediated growth factor deprivation
28. Expression level of bcl-2 determines anti- or proapoptotic function
29. Apoptotic conversion: Evidence for exchange of genetic information between prostate cancer cells mediated by apoptosis